Skip to main content
. 2020 Nov 30;99(2):112–124. doi: 10.2471/BLT.20.267112

Table 3. Cost of COVID-19 according to cost component and COVID-19 diagnosis, China, January–March 2020.

Cost component Cost, million ¥
Total cost, million ¥ (million US$)
People not considered to have had COVID-19 Close contacts diagnosed as COVID-19 negative Suspected cases diagnosed as COVID-19 negative
Confirmed cases surviving

Confirmed cases died
Non-severe Severe Critical
Routine health care
Identification and diagnosis N/A 95.16 13.30 33.91 5.74 0.27 2.32 150.70 (21.81)
Medical observationa N/A 261.85 17.50 N/A N/A N/A N/A 279.35 (40.43)
Inpatient care N/A N/A 13.46 314.00 169.70 46.79 405.31 949.26 (137.37)
Medicines N/A N/A N/A 22.18 377.07 30.92 267.86 698.03 (101.02)
Treatment for pre-existing conditions N/A N/A N/A 2.20 45.43 2.37 20.54 70.54 (10.21)
Follow-up for recovered cases N/A N/A N/A 1.45 0.25 0.01 N/A 1.71 (0.25)
Subtotal N/A 357.01 44.26 373.74 598.19 80.36 696.03 2 149.59 (311.08)
Non-routine health careb N/A N/A N/A N/A N/A N/A N/A 2 106.81 (304.89)
Quarantine for test-negative cases N/A 803.17 33.41 N/A N/A N/A N/A 836.58 (121.07)
Productivity loss 2 638 379.36 2 635.33 169.86 328.63 62.10 3.41 26.51 2 641 605.20 (382 287.29)
Total (societal cost) 2 638 379.36 3 795.51 247.53 702.37 660.29 83.77 722.54 2 646 698.18 (383 024.34)c

COVID-19: coronavirus disease 2019; N/A: not applicable; US$: United States dollars;

¥: Chinese yuan.

a Medical observation of close contacts and/or suspected cases before receiving a diagnosis of COVID-19.

b Includes risk subsidy for health-care staff and emergency funds for construction of temporary emergency buildings and non-routine procurement of additional medical supplies and equipment.

c Column total. We could not assign the cost of non-routine health care to any specific individual patient group so we only report the total cost of non-routine health care in the last column; therefore, the cost of non-routine health care is not reflected in the total societal cost for each patient subgroup (last row).